Skip to main content
Journals

Resident-Run Clinic for Nonsurgical Injectable Facial Aesthetics: A 5-Year Institutional Experience

Aesthetic Surgery Journal Open Forum
Aesthetic Surgery Journal Open Forum

Authors: Sydney Somers, BS , Kaylee B Scott, MD , Ashraf Patel, MD , Chase Hart, BS , Alexandra Vitale, BS , McKenna Waller, BS , Rachelle Clarke, BS , Aaron Dadzie, BSA , Devin Eddington, MS , Cori Agarwal, MD, Courtney Crombie, MD

Abstract: Resident-run clinics (RRCs) have become an important component of plastic surgery training. This study evaluates outcomes from a longitudinal RRC focused on neuromodulator and soft tissue filler injections over a 5-year period. The aim of this study was to assess clinical outcomes, patient retention, resident experience by postgraduate year (PGY) level, and the safety of RRCs as a training model. A retrospective review of patients seen in our institution's RRC from January 2020 to September 2024 was performed. Variables included demographics, injectable type and anatomic location, revision rate (overall and by PGY), complication rate, patient retention, and surgical conversion. A total of 380 patients (92.1% female, mean age 41) accounted for 1168 encounters (mean 3.3 visits/patient). Thirty-seven residents participated during the study period. Neuromodulator, filler, and combined treatments comprised 55.3%, 20.9%, and 23.7% of encounters, respectively. Corrugators (91%) and lips (74%) were the most common neuromodulator and filler sites. The overall complication rate was 0.17% (infection and eyebrow ptosis), and the revision rate was 5.2%, most commonly because of perceived ineffectiveness (58.7%) or asymmetry (38.1%). Revision rates decreased with advancing PGY (PGY-1: 9.0% vs PGY-6: 3.0%). Sixty-five percent of patients returned for at least 1 subsequent visit, and 5.5% later scheduled surgery with a resident or attending. Nonsurgical RRCs provide a safe, effective training environment for progressive autonomy in aesthetic injectables while maintaining low complication and revision rates comparable to other practice settings.

JOURNAL ARTICLE

Related Articles

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. This study’s primary objective is to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting.
Upper facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment; yet, comprehensive synthesized evidence is limited.
Hyaluronidase is often described as “dissolving” dermal filler, but this term oversimplifies how the enzyme actually interacts with long-standing filler within living tissue. This article explains why hyaluronidase more accurately modifies a complex filler–tissue system rather than completely eliminating filler, and why clearer terminology improves patient understanding, clinical decision-making, and ethical practice in aesthetic medicine.
Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.